Comment
. 2003 Jul 8;108(1):e5; author reply e5.
doi: 10.1161/01.CIR.0000080080.76333.38.
Randomized controlled trial evidence that estrogen replacement therapy reduces the progression of subclinical atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease
- PMID: 12847059
- DOI: 10.1161/01.CIR.0000080080.76333.38
Item in Clipboard
Comment
Randomized controlled trial evidence that estrogen replacement therapy reduces the progression of subclinical atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease
Circulation.
.
No abstract available
Comment on
-
Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein.Circulation. 2002 Apr 23;105(16):1879-82. doi: 10.1161/01.cir.0000016173.98826.88. Circulation. 2002. PMID: 11997270 Clinical Trial.
-
Hormone replacement therapy and heart disease: replacing dogma with data.Circulation. 2003 Jan 7;107(1):2-4. doi: 10.1161/01.cir.0000048891.81129.2d. Circulation. 2003. PMID: 12515732 No abstract available.
Similar articles
-
Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.Ann N Y Acad Sci. 2006 Nov;1089:444-53. doi: 10.1196/annals.1386.046. Ann N Y Acad Sci. 2006. PMID: 17261787 Review.
-
Postmenopausal hormone replacement therapy and prevention: no chance for celebration? What should doctors do? A personal opinion.Ital Heart J. 2002 Dec;3(12):693-8. Ital Heart J. 2002. PMID: 12611118 No abstract available.
-
Postmenopausal hormone therapy: new questions and the case for new clinical trials.Menopause. 2006 Jan-Feb;13(1):139-47. doi: 10.1097/01.gme.0000177906.94515.ff. Menopause. 2006. PMID: 16607110
-
[Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].Wiad Lek. 2006;59(5-6):377-82. Wiad Lek. 2006. PMID: 17017486 Review. Polish.
-
[Hormonal supplements for postmenopausal women: no evidence of protection against cardiovascular disease].Ned Tijdschr Geneeskd. 2001 Jan 13;145(2):61-4. Ned Tijdschr Geneeskd. 2001. PMID: 11225257 Review. Dutch.
Cited by
-
Neuroprotection with non-feminizing estrogen analogues: an overlooked possible therapeutic strategy.Horm Behav. 2013 Feb;63(2):278-83. doi: 10.1016/j.yhbeh.2012.03.013. Epub 2012 Apr 3. Horm Behav. 2013. PMID: 22498694 Free PMC article. Review.
-
The assessment of non-feminizing estrogens for use in neuroprotection.Brain Res. 2011 Mar 16;1379:61-70. doi: 10.1016/j.brainres.2010.11.058. Epub 2010 Nov 25. Brain Res. 2011. PMID: 21111714 Free PMC article. Review.
-
Mitochondrial mechanisms of estrogen neuroprotection.Biochim Biophys Acta. 2010 Oct;1800(10):1113-20. doi: 10.1016/j.bbagen.2009.11.013. Epub 2009 Nov 26. Biochim Biophys Acta. 2010. PMID: 19931595 Free PMC article. Review.
-
Role of protein phosphatases and mitochondria in the neuroprotective effects of estrogens.Front Neuroendocrinol. 2009 Jul;30(2):93-105. doi: 10.1016/j.yfrne.2009.04.013. Epub 2009 May 3. Front Neuroendocrinol. 2009. PMID: 19410596 Free PMC article. Review.
-
17beta-Estradiol reverses shear-stress-mediated low density lipoprotein modifications.Free Radic Biol Med. 2006 Aug 15;41(4):568-78. doi: 10.1016/j.freeradbiomed.2006.04.010. Epub 2006 Apr 26. Free Radic Biol Med. 2006. PMID: 16863990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
